Celldex Therapeutics (CLDX) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $73.6 million.
- Celldex Therapeutics' Operating Expenses rose 3308.21% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 3162.2%. This contributed to the annual value of $202.1 million for FY2024, which is 2519.62% up from last year.
- According to the latest figures from Q3 2025, Celldex Therapeutics' Operating Expenses is $73.6 million, which was up 3308.21% from $64.6 million recorded in Q2 2025.
- In the past 5 years, Celldex Therapeutics' Operating Expenses registered a high of $73.6 million during Q3 2025, and its lowest value of $16.9 million during Q2 2021.
- Moreover, its 5-year median value for Operating Expenses was $36.6 million (2022), whereas its average is $39.9 million.
- Per our database at Business Quant, Celldex Therapeutics' Operating Expenses plummeted by 2762.72% in 2021 and then surged by 11606.97% in 2022.
- Celldex Therapeutics' Operating Expenses (Quarter) stood at $20.7 million in 2021, then skyrocketed by 42.68% to $29.5 million in 2022, then surged by 75.46% to $51.8 million in 2023, then grew by 10.52% to $57.2 million in 2024, then grew by 28.7% to $73.6 million in 2025.
- Its Operating Expenses stands at $73.6 million for Q3 2025, versus $64.6 million for Q2 2025 and $63.4 million for Q1 2025.